Study of neoadjuvant Letrozole combined with standerd chemotherapy for postmenopausal women with Endocrine-responsive Breast Cancer(subject of stage2,3A)
Phase 2
Suspended
- Conditions
- Postmenopausal, hormone-receptor positive and resectable primary breast cancer
- Registration Number
- JPRN-UMIN000002447
- Lead Sponsor
- iigata Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Female
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1.Serious complications ( e.g malignant hypertension, CHF, hepatic failure, MI within 6 months, PE, arrhythmia treatment needed, infection, hemorrhagic tendency ) 2.Hepatitis B 3.Serious Diabetes mellitus 4.Infection disease 5.Active multiple cancer 6.Edema 7.Inflammatory breast cancer 8.Synchronous bilateral breast cancer 9.History of drug-hypersensitivity 10.Patients have been treated with steroid or hormone replacement therapy or raloxifene 11.Mental disease 12.Osteoporosis, treated with bisphosphonate at present 13.Patient judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological response
- Secondary Outcome Measures
Name Time Method Clinical response rate,Breast Conserving Surgery rate,Safety